A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Active opportunistic infection or neoplasm.
• •High likelihood of death during study.
• •Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease.
• •Donation of \> 1 unit blood or acute loss of blood within one month of study entry.
• •Patients with the following prior conditions are excluded:
• •History of opportunistic infection.
• •Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone.
• •Prior Medication:
• •Excluded:
• •Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.